Inaugural MCI Masterclass 2021
This Australia-first event led by Associate Professor Michael Woodward and Associate Professor Mark Yates brought together leading experts to present the latest evidence and insights on Driving Change in the early identification and management of patients with mild cognitive impairment.
Cognitive Impairment Screening Tool
Memory Expert resources
APP 2022 Conference Lecture - Mild Cognitive Impairment, what pharmacists need to know.
Early signs of Alzheimer’s disease
The role of Souvenaid® in the management of patients with early Alzheimer’s disease.
Associate Professor Michael Woodward gives a 5 minute lecture on the evidence for the medical food Souvenaid® and its role in the management of patients with early Alzheimer’s disease including mild cognitive impairment.
Understanding Mild Cognitive Impairment (MCI)
MCI causes cognitive changes that are serious enough to be noticed by the person affected and by family and friends.1 It is estimated that people with MCI have a 3 to 5 times increased risk of developing dementia and yet it can be challenging to differentiate MCI from normal ageing.2